Please login to the form below
licensing agreements
This page shows the latest licensing agreements news and features for those working in and with pharma, biotech and healthcare.
Merck’s COVID-19 antiviral under review in Europe by EMA
The company has entered into similar agreements with governments worldwide, including the UK government, which announced last week that it had ordered 480, 000 courses of the antiviral in addition to ... It has previously announced non-exclusive
Latest news
-
First oral antiviral drug for COVID-19 reviewed by Health Canada
Merck has also signed voluntary licensing agreements with five Indian generic drug manufacturers to expand access to molnupiravir, and non-exclusive voluntary licensing agreements with other generic manufactures to offer the
-
‘Post-Brexit landscape for EU-wide IP Rights: The Story So Far’
Licensing. Also of relevance to the pharmaceutical sector is the impact of Brexit on IP licensing. ... Future licence agreements should be drafted to specifically address the effect of Brexit on any relevant provisions.
-
GSK unveils access plan for low-income countries
The MPP was set up in 2010 and focuses on voluntary licensing agreements with companies serving in low-income countries and LMICs. ... month. Another firm active in this area is Gilead Sciences, which signed licensing deals with Indian generics companies
-
AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio
As well as resisting the $100bn overture from Pfizer earlier this year, Soriot has instigated a range of acquisitions and licence agreements. ... These include licensing the WEE1 inhibitor MK-1775 from Merck &Co, the $500m buyout of biotech Amplimmune
-
AZ buys into ADC sector with $440m Spirogen deal
Pushes into the market for antibody-drug conjugates. AstraZeneca has made a push into the market for antibody-drug conjugates (ADCs) via the acquisition of Spirogen and a licensing deal with ... The agreements will allow it to "accelerate ADCs into the
More from news
Approximately 0 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Internal teams led the clinical side of R&D, while business development teams worked to identify collaboration opportunities, including partnerships or licence agreements with other companies to build their pipelines. ... They also can help identify
-
The search for effective drug treatments for COVID-19
Beyond this network, in the developing world, we have entered into non-exclusive voluntary licensing agreements with nine generic manufacturers to further expand access and supply of remdesivir. ... These agreements are royalty-free during the pandemic
-
Leo has its eyes on the prize
We will be very active in building partnerships and licensing agreements.
-
A new route to market
Licensing agreements. A common model for many small to medium sized biotech companies taking a first step in exporting is to license a product or technology to a local market partner - ... Licensing agreements are rarely straightforward, and a level of
-
Pharma deals during October 2013
Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month. ... Pre-existing out-licensing agreements, which include milestones and royalties, remain in effect and these have been transferred into a holding company 75 per cent
More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
